Chemotherapy DNA PARP Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Serine-Threonine Kinase Inhibitors Tyrosine Kinase Inhibitors FGF | Pancreatic Adenocarcinoma | HER2 Negative Breast Cancer | Breast Cancer | Biliary Tract Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Triple Negative Breast Cancer | Urothelial Cancer | Melanoma | Endometrial Cancer | Hormone Receptor Positive Breast Cancer |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CTLA4 inhibitor | |||||||||||||
FOLFIRINOX | |||||||||||||
PARP inhibitor | |||||||||||||
CX-5461 | |||||||||||||
olaparib | |||||||||||||
cisplatin + gemcitabine | |||||||||||||
talazoparib | |||||||||||||
rucaparib | |||||||||||||
everolimus | |||||||||||||
oxaliplatin | |||||||||||||
durvalumab | |||||||||||||
nivolumab + ipilimumab | |||||||||||||
rucaparib + E 3810 | |||||||||||||
ABT-888 | |||||||||||||
ipilimumab + niraparib | |||||||||||||
carboplatin + docetaxel | |||||||||||||
lenvatinib |